CliffBio
small molecule

ANGELIQ

DROSPIRENONE; ESTRADIOL

Loss of exclusivityOctober 2031latest FDA-listed patent expiry
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameANGELIQ
Active ingredientDROSPIRENONE; ESTRADIOL
Strength0.25MG;0.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2012
Marketing statusRX

Listed patents

PatentExpiresType
8906890October 2031product

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ANGELIQ patent cliff — loss of exclusivity October 2031 | CliffBio